---
document_datetime: 2024-04-05 15:22:00
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lonsurf-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lonsurf-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.9207945
conversion_datetime: 2025-12-27 20:19:47.45825
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lonsurf

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| IB/0029              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 04/04/2024                          | n/a                                         |                                  |                                   |
| PSUSA/10517 /202303  | Periodic Safety Update EU Single assessment - trifluridine / tipiracil                                                                        | 26/10/2023                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0026     | Extension of indication to include treatment of patients with refractory metastatic colorectal cancer for LONSURF in combination with bevacizumab based on results from study SUNLIGHT (CL3-95005-007); This is an open-label, randomised, phase III study comparing trifluridine/tipiracil in combination with bevacizumab to trifluridine/tipiracil monotherapy in patients with refractory metastatic colorectal cancer. As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC. The package leaflet is updated in accordance. The updated RMP version 10 has also been submitted. In addition, the MAH took the opportunity to update section 4.6 of the SmPC and the Package leaflet accordingly. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   | 22/06/2023   | 26/07/2023   | SmPC and PL     | Please refer to Scientific Discussion 'Product Name-H-C- 003897-II-0026   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|---------------------------------------------------------------------------|
| II/0025     | B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 15/06/2023   | n/a          |                 |                                                                           |
| IAIN/0027/G | This was an application for a group of variations. B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.b - Replacement or addition of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 24/05/2023   | 26/07/2023   | Annex II and PL |                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0024/G | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) A.7 - Administrative change - Deletion of manufacturing sites | 27/01/2022 | n/a |

<div style=\"page-break-after: always\"></div>

|           | period - Extension or introduction of a re-test period/storage period supported by real time data B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of parameter)   |            |            |    | period/storage an obsolete   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|------------------------------|
| N/0023    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 15/09/2021 | 26/07/2023 | PL |                              |
| IB/0022   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 09/04/2021 | n/a        |    |                              |
| IAIN/0021 | B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of State - AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 08/02/2021 | n/a        |    | a Member                     |

<div style=\"page-break-after: always\"></div>

| R/0020              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 15/10/2020   | 14/12/2020   | SmPC and PL   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Lonsurf in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                                                           |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10517 /202003 | Periodic Safety Update EU Single assessment - trifluridine / tipiracil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/10/2020   | n/a          |               | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0016             | Update of sections 4.2, 4.4 and 5.2 of the SmPC in order to update information on patients with severe renal impairment based on final results from study TO-TAS-102-107 (A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients With Advanced Solid Tumors and Varying Degrees of Renal Impairment). The Package Leaflet is updated accordingly. The updated RMP version 8.0 has also been agreed. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the RMP in line with the template revision 2 of the good Pharmacovigilance practice module V guideline and to align the PI to the QRD template version 10.1. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 27/02/2020   | 01/04/2020   | SmPC and PL   | For patients with severe renal impairment a starting dose of 20 mg/m2 twice daily is recommended. One dose reduction to a minimum dose of 15 mg/m2 twice daily is permitted based on individual safety and tolerability. Dose escalation is not permitted after it has been reduced. Administration is not recommended in patients with end stage renal disease as there are no data available for these patients. For more information please refer to the Summary of Product Characteristics. |
| IA/0018/G           | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/01/2020   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0017/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its | 31/10/2019 | n/a |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |              |                                                                          |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------|--------------------------------------------------------------------------|
| PSUSA/10517 /201903 | Periodic Safety Update EU Single assessment - trifluridine / tipiracil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 03/10/2019 | n/a        |              | PRAC Recommendation - maintenance                                        |
| II/0012             | Extension of Indication to include the treatment, as monotherapy, of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two systemic treatment regimens for advanced disease for Lonsurf; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 7.0 has also been submitted and updated in accordance with Template Rev 2. For clarification, the term monotherapy has also been added to the existing indication in metastatic colorectal cancer. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 25/07/2019 | 03/09/2019 | SmPC and PL  | Please refer to the published Assessment Report Lonsurf H- 3897-II-0012. |
| N/0015              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 16/07/2019 | 03/09/2019 | PL           |                                                                          |
| IA/0013/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 03/04/2019 | 03/09/2019 | Annex II and |                                                                          |

<div style=\"page-break-after: always\"></div>

|                     | A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter   |            |     | PL   |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|-----------------------------------|
| PSUSA/10517 /201803 | Periodic Safety Update EU Single assessment - trifluridine / tipiracil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 04/10/2018 | n/a |      | PRAC Recommendation - maintenance |
| PSUSA/10517 /201709 | Periodic Safety Update EU Single assessment - trifluridine / tipiracil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 12/04/2018 | n/a |      | PRAC Recommendation - maintenance |
| PSUSA/10517 /201704 | Periodic Safety Update EU Single assessment - trifluridine / tipiracil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 30/11/2017 | n/a |      | PRAC Recommendation - maintenance |
| IB/0009             | C.I.11.z - Introduction of, or change(s) to, the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 17/11/2017 | n/a |      |                                   |

<div style=\"page-break-after: always\"></div>

|                     | obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|-----------------------------------|
| IB/0008             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                 | 14/08/2017 | 07/03/2018 | SmPC                |                                   |
| PSUSA/10517 /201610 | Periodic Safety Update EU Single assessment - trifluridine / tipiracil                                                                                                                                                                                                                                                                                                                                                                                                                                    | 05/05/2017 | n/a        |                     | PRAC Recommendation - maintenance |
| IA/0006             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                              | 24/04/2017 | n/a        |                     |                                   |
| IAIN/0005/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 24/04/2017 | 07/03/2018 | Annex II and PL     |                                   |
| II/0002/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 23/03/2017 | 07/03/2018 | SmPC, Labelling and |                                   |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | PL   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| II/0003   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                           | 16/03/2017 | n/a |      |
| IAIN/0001 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                      | 27/07/2016 | n/a |      |